Cellectis (CLLS) Income towards Parent Company (2015 - 2026)
Cellectis' (CLLS) quarterly Income towards Parent Company came in at -$0.18 in Q1 2026, little changed year-on-year from -$0.18 in Q1 2025, and up 30.77% quarter-over-quarter from -$0.26 in Q4 2025.
Cellectis (CLLS) Income towards Parent Company (2015 - 2026) Analysis & Trends
Cellectis' Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$0.18 for Q1 2026.
- On a quarterly basis, Income towards Parent Company changed 0.0% year-over-year to -$0.18 in Q1 2026; TTM through Mar 2026 was -$23.1 million, a 45.41% increase from a year earlier, with the FY2025 full-year figure at -$0.67, up 100.0% from the prior year.
- Income towards Parent Company rose to -$0.18 in Q1 2026 per CLLS's latest filing, from -$0.26 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $5.9 million in Q4 2024 and bottomed at -$41.8 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$18.9 million (2022), against an average of -$15.7 million.
- Across the five-year window, Income towards Parent Company plunged 168.88% in 2022 and jumped 118.76% in 2024, its largest moves.
- Year by year, Income towards Parent Company stood at -$26.8 million in 2022, then tumbled by 55.86% to -$41.8 million in 2023, then soared by 114.17% to $5.9 million in 2024, then plunged by 100.0% to -$0.26 in 2025, then jumped by 30.77% to -$0.18 in 2026.
- Per Business Quant, the three latest CLLS Income towards Parent Company figures stand at -$0.18 (Q1 2026), -$0.26 (Q4 2025), and $589000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.18 |
| Dec 31, 2025 | -0.26 |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | -23.74 Mn |
| Mar 31, 2025 | -0.18 |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | -23.06 Mn |
| Jun 30, 2024 | -25.27 Mn |
| Mar 31, 2024 | 5.64 Mn |
| Dec 31, 2023 | -41.80 Mn |
| Sep 30, 2023 | -17.48 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Mar 31, 2023 | -30.07 Mn |
| Dec 31, 2022 | -26.82 Mn |
| Sep 30, 2022 | -28.47 Mn |
| Jun 30, 2022 | -18.95 Mn |
| Mar 31, 2022 | -31.91 Mn |
| Dec 31, 2021 | -25.00 Mn |
| Sep 30, 2021 | -37.41 Mn |
| Jun 30, 2021 | -39.92 Mn |